Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
BEVERLY, Mass. and TORONTO, April 26, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that it will host a webcast investor presentation on Tuesday, May 1st at 11:00 AM ET.
During the webcast, David Wolf, CEO will provide an introductory presentation that will cover key areas of Hamilton Thorne’s business. Topics will cover: products and services, the current state of the industry, expected market trends, recent results, growth strategy and future objectives. During parts of the presentation, investors will have an opportunity to ask relevant questions and interact with management.
To listen to the live webcast or to ask questions during the live event, please pre-register at the following link: https://event.webcasts.com/starthere.jsp?ei=1189984&tp_key=78d2cb4865. An archived version of the webcast and presentation will be available on the Company's website at www.hamiltonthorne.com following the event.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO Michael Bruns, CFO
Hamilton Thorne Ltd. Hamilton Thorne Ltd.
978-921-2050 978-921-2050
[email protected] [email protected]
Glen Akselrod
Bristol Investor Relations
905-326-1888
[email protected]
